Head-to-head · WeighScore
Lavender Sky Health vs Nucific
The verdict
Lavender Sky Health takes it — 68.4/100 to 56.2/100.
Lavender Sky Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lavender Sky Health is a marketplace of about ten compounding pharmacies rather than a single-price provider, each with its own ladder of prepaid tiers and month-to-month plans.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Lavender Sky Health | Nucific |
|---|---|---|
| WeighScore | 68.4/100 | 56.2/100 |
| Grade | C | C |
| Scorecard rank | #152 | #418 |
| Semaglutide | $139/mo (starting dose, month to month, Southend Pharmacy, compounded) | Not disclosed |
| Tirzepatide | $149/mo (starting dose, month to month, ReviveRx, compounded) | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #152 · C
Strengths
- The treatment-plan pricing page publishes every pharmacy's full ladder rather than one headline figure, so the cheaper prepaid tiers are visible alongside the monthly ones
- A genuine month-to-month starter plan exists with no prepay, and the cheapest of them is what is filed above — Southend for semaglutide, ReviveRx for tirzepatide
- Compounded plans include the price of the medication, and shipping and supplies are stated as included
- Both semaglutide and tirzepatide are offered, across roughly ten named compounding pharmacies
Where it loses points
- This is a marketplace, not one price: every figure belongs to a named pharmacy on a named plan, and the pharmacy and plan have to travel with the number for it to mean anything
- Most of the ladder is prepaid — Tier plans need 8-10 weeks up front and Extended plans 3-4 months — and only a handful of the pharmacies publish a month-to-month starter plan at all
- Brand-name plans add a separate $25 monthly treatment-plan fee and explicitly do not include the price of the medication; only the compounded plans include it
- No price appears on the homepage, and the pricing page is the only place the ladders are published
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #418 · C
Strengths
- Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
- Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
- Discloses that featured patients were compensated for their time
- Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
- Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue
Where it loses points
- No price is published anywhere; every option is gated behind a three-minute quiz
- The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
- A BBB Accredited A+ claim is displayed without a link to the BBB profile
- No state list and no named pharmacy, only licensed U.S. pharmacies
- Before-and-after photographs are used alongside compensated testimonials
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.